Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:2662
Structure:
Synonyms:
169590-42-5
184007-95-2
194044-54-7
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonami
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AI-525
Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)-
Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celecox
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [USAN]
Celocoxib
CHEBI:41423
cMAP_000027
D00567
DB00482
DivK1c_000893
Heumann brand of celecoxib
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
KS-1041
LS-31667
Mack brand of celecoxib
MLS001165684
MLS001195656
MLS001304708
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Parke Davis brand of celecoxib
Pfizer brand of celecoxib
Pharmacia brand of celecoxib
Pharmacia Spain brand of celecoxib
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
Searle brand of celecoxib
SMR000550473
Solexa
SPBio_001512
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
STOCK6S-51468
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
ATC-Codes:
Side-Effects:
Side-EffectFrequency
headache0.1465
hypertension0.125
dyspepsia0.0776
upper respiratory tract infection0.0754
diarrhea0.058166668
sinusitis0.0472
gastroesophageal reflux disease0.047
nausea0.036857147
abdominal pain0.035800003
back pain0.031200001
dyspnea0.028
insomnia0.023
rash0.021599999
pharyngitis0.0182
rhinitis0.017199999
flatulence0.017199999
peripheral edema0.016999999
vomiting0.0165
dizziness0.015833333
vasculitis0.0010
fever0.0010
pulmonary embolism0.0010
vascular disorders0.0010
gangrene0.0010
osteitis0.0010
myositis0.0010
interstitial nephritis0.0010
pancytopenia0.0010
ventricular fibrillation0.0010
ulceration0.0010
esophageal perforation0.0010
pain0.0010
pancreatitis0.0010
erythema multiforme0.0010
epilepsy0.0010
toxic epidermal necrolysis0.0010
gastrointestinal bleeding0.0010
myocardial infarction0.0010
cardiac disorders0.0010
hypoglycemia0.0010
thrombocytopenia0.0010
hyponatremia0.0010
intestinal perforation0.0010
jaundice0.0010
syncope0.0010
stevens johnson syndrome0.0010
acute renal failure0.0010
leukopenia0.0010
thrombophlebitis0.0010
heart failure0.0010
congestive heart failure0.0010
bleeding0.0010
hepatitis0.0010
menstrual disorder0.0010
skin erythema0.0010
mediastinal disorders0.0010
allergic reactions0.0010
cerebrovascular accident0.0010
bronchospasm0.0010
angioedema0.0010
anosmia0.0010
confusion0.0010
acute pancreatitis0.0010
connective tissue disorders0.0010
aseptic meningitis0.0010
colitis0.0010
cholelithiasis0.0010
arthritis0.0010
breast disorders0.0010
transient ischemic attacks0.0010
ataxia0.0010
sepsis0.0010
deep venous thrombosis0.0010
angina0.0010
aplastic anemia0.0010
hallucinations0.0010
exfoliative dermatitis0.0010
anaphylactic shock0.0010
agranulocytosis0.0010
dysmenorrhea0.0010
liver failure0.0010
intracranial hemorrhage0.0010
decreased hearing0.0010
increased sweating0
tinnitus0
neuropathy0
synovitis0
blurred vision0
photosensitivity0
pruritus0
hypophosphatemia0
thrombocythemia0
proteinuria0
pneumonia0
paresthesia0
urinary frequency0
skin nodule0
elevated blood pressure0
breast neoplasm0
stomatitis0
tachycardia0
vaginal hemorrhage0
weight gain0
uveitis0
neck rigidity0
vaginitis0
migraine0
bronchitis0
cataract0
sinus bradycardia0
vertigo0
viral infection0
liver function tests abnormal0
urticaria0
hyperchloremia0
tendinitis0
tenesmus0
abdominal pain upper0
tooth disorder0
myalgia0
dry skin0
urinary incontinence0
urinary tract infection0
sgot increased0
alkaline phosphatase increased0
eye pain0
dry mouth0
adenomas0
coronary artery disease0
cough0
cystitis0
cyst0
deafness0
dysphagia0
dermatitis0
contact dermatitis0
diabetes mellitus0
diverticulitis0
somnolence0
dysuria0
ear pain0
ecchymosis0
edema0
constipation0
conjunctivitis0
albuminuria0
alopecia0
anemia0
anorexia0
anxiety0
aortic valve incompetence0
arthralgia0
asthenia0
bacterial infections0
clotting0
moniliasis0
cellulitis0
cerebral infarction0
cerebrovascular disorder0
chest pain0
epicondylitis0
epistaxis0
eructation0
arthrosis0
kidney calculus0
labyrinthitis0
laryngitis0
leg cramps0
breast pain0
melena0
fungal infection0
nail disorder0
nasopharyngitis0
nervousness0
neuralgia0
gastroenteritis0
otitis media0
ovarian cyst0
influenza0
infection0
esophagitis0
fatigue0
vitreous floaters0
flushing0
gastritis0
glaucoma0
hematuria0
hemorrhoids0
hiatal hernia0
herpes simplex0
herpes zoster0
hypercholesterolemia0
hyperglycemia0
hypersensitivity0
hypokalemia0
palpitations0

Target

show target details
Uniprot ID:KLK3_HUMAN
Synonyms:
Gamma-seminoprotein
Kallikrein-3
P-30 antigen
Prostate-specific antigen
PSA
Semenogelase
Seminin
EC-Numbers:3.4.21.77
Organism:Homo sapiens
Human
PDB IDs:1PFA 2PSA 2ZCH 2ZCK 2ZCL
Structure:
2ZCL

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

14764122
A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.. R S Pruthi; J E Derksen; D Moore (2004) BJU international display abstract
OBJECTIVES: To evaluate the efficacy of the cyclooxygenase (COX)-2 inhibitor celecoxib in prostate-specific antigen (PSA) recurrent prostate cancer after definitive radiation therapy (RT) or radical prostatectomy (RP), as recent evidence showed that COX-2 inhibitors have potent antitumour activity in prostate cancer both in vitro and in vivo but there are no human trials. PATIENTS AND METHODS: Twelve patients who had biochemical relapse after RT or RP were treated with celecoxib 200 mg twice daily. Follow-up PSA levels to assess efficacy were obtained at 3, 6 and 12 months after initiating treatment. Data were evaluated by calculating PSA doubling times and the slope of the curve of logPSA vs time, to assess rate of PSA rise before and after celecoxib treatment for each patient. Serum testosterone levels were also measured. RESULTS: Eight of the 12 patients had significant inhibition of their serum PSA levels after 3 months of treatment; five had a decline in their absolute PSA level and three a stabilization of the level. Of the remaining four patients, three had a marked decrease in their PSA doubling time, with a mean increase (i.e. slowing) of 3.1 times that before treatment. The short-term responses at 3 months also continued at 6 and 12 months. From the slope of log PSA vs time there was a significant flattening of the rate of PSA rise (P = 0.001). There was a significant change of patients with rapid doubling times towards slower doubling times or even stable/declining PSA values after treatment with celecoxib (P = 0.029). There was no significant change in testosterone levels, suggesting an androgen-independent mechanism. CONCLUSIONS: COX-2 inhibitors may have an effect on serum PSA levels in patients with biochemical progression after RT or RP. These results suggest that COX-2 inhibitors may help to delay or prevent disease progression in these patients, and thereby help extend the time until androgen deprivation therapy. Further study with more patients is currently underway to better evaluate the clinical potential of COX-2 inhibitors as an antitumour agents in prostate cancer.